Posts Tagged ‘Off-Label Marketing’

  • Celgene Pays $280 Million for Off-Label Marketing of Cancer Drugs

    Celgene, a pharmaceutical manufacturer based out of New Jersey, paid $280 million following a whistleblower suit which claimed they promoted their popular cancer drugs for unapproved purposes. The two drugs in question, Thalomid and Revlimid, are Celgene’s highest-grossing products, together accounting for $8.4 billion in annual revenue – an astounding 75% of the company’s profits. […]